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Abstract. Substantial evidence indicates that aspirin and 
related non-steroidal anti-inflammatory drugs (NSAIDs) have 
potential as chemopreventative/therapeutic agents. However, 
these agents cannot be universally recommended for preven-
tion purposes due to their potential side-effect profiles. Here, 
we compared the growth inhibitory and mechanistic activity 
of aspirin to two novel analogues, diaspirin (DiA) and fumaryl 
diaspirin (F-DiA). We found that the aspirin analogues inhib-
ited cell proliferation and induced apoptosis of colorectal 
cancer cells at significantly lower doses than aspirin. Similar 
to aspirin, we found that an early response to the analogues 
was a reduction in levels of cyclin D1 and stimulation of 
the NF-κB pathway. This stimulation was associated with a 
significant reduction in basal levels of NF-κB transcriptional 
activity, in keeping with previous data for aspirin. However, in 
contrast to aspirin, DiA and F-DiA activity was not associated 
with nucleolar accumulation of RelA. For all assays, F-DiA 
had a more rapid and significant effect than DiA, identifying 
this agent as particularly active against colorectal cancer. 
Using a syngeneic colorectal tumour model in mice, we found 
that, while both agents significantly inhibited tumour growth 
in vivo, this effect was particularly pronounced for F-DiA. 
These data identify two compounds that are active against 
colorectal cancer in vitro and in vivo. They also identify a 
potential mechanism of action of these agents and shed light 
on the chemical structures that may be important for the anti-
tumour effects of aspirin.
Introduction
In Europe, colorectal cancer (CRC) is responsible for 13.6% 
of all cancers (1). Despite continuing research, the five-year 
age-standardised survival rate in the UK remains approxi-
mately 46% (CRUK). Present treatment imparts considerable 
morbidity. Therefore, a number of strategies are being pursued 
to reduce this disease burden. Of these strategies, early 
detection (including enhanced population screening and 
prophylactic surveillance in high risk groups) and prevention 
are considered the most promising.
Abundant evidence indicates that non-steroidal 
anti-inflammatory drugs (NSAIDs), including aspirin, are 
anti-tumorigenic and can prevent CRC (2-6 and refs. therein). 
For instance, in chemical and genetic animal models, NSAIDs 
reduce the initiation and progression of CRC (or aberrant crypt 
foci) (7-11). Recent meta-analysis of a large number of patient 
studies indicates that treatment with daily aspirin for 5 years 
or longer reduces the risk of developing multiple cancer types, 
including CRC (12). Furthermore, in a randomised controlled 
trial of carriers with Lynch syndrome (CAPP2 study), inges-
tion of a 600 mg daily dose of aspirin for ~2 years was capable 
of substantially reducing CRC incidence (13). Aspirin has also 
been proposed to suppress metastasis (14), and regular aspirin 
use after diagnosis of non-metastatic CRC is associated with a 
reduced CRC-specific mortality, an association that was stron-
gest when the primary tumour overexpressed cyclooxygenase-2 
(COX-2) (15). Despite these promising data, the use of aspirin 
for chemopreventative purposes universally is restricted by the 
potential gastropathy associated with long-term use (16). Thus, 
there is an overwhelming rationale to identify aspirin-related 
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compounds that retain the specific toxicity to CRC but are 
safer and more effective than aspirin itself.
A number of derivatives of the salicylate/aspirin 
molecule have been tested for toxicity to cancer cells. For 
example, 5-aminosalicylic acid (mesalazine) improves 
replication fidelity in HCT-116 CRC cells (17,18). Moreover, 
NCX-4040 (an NO releasing aspirin, 2-(acetyloxy)benzoic 
acid 4-[(nitrooxy)methyl]phenyl ester) can also suppress 
microsatellite instability (19) and sensitise human colon 
cancer cells, cultured in vitro and transplanted in vivo in 
mice, to oxaliplatin (20). Another nitro-derivative of aspirin, 
NCX-4016 (2-(acetyloxy)benzoic acid 3-[(nitrooxy)methyl]
phenyl ester), inhibits epidermal growth factor signalling 
in human ovarian carcinoma and inhibits tumour growth in 
ovarian cancer xenografts (21). MDC-43, a para-positional 
isomer of phosphoaspirin (4-[(diethoxyphosphoryloxy)methyl]
phenyl 2-acetoxybenzoate) reportedly inhibited the growth 
of cells derived from colon, lung, liver, pancreas and breast 
cancer (22).
The mechanism(s) by which NSAIDs protect against CRC 
are a matter of debate. As NSAIDs inhibit cyclooxygenase 
activity and prostaglandins have been implicated in neoplastic 
growth (23), a significant focus of research has understand-
ably been into the development of agents that can reduce 
specific COX activity (24,25). However, there is a growing 
consensus that NSAIDs can exert their anti-proliferative 
activities via COX-independent effects (26,27). Other mecha-
nisms that have been invoked for the anti-proliferative effects 
of these agents include: inhibition of the transcription factor 
NF-κB (28); activation of the p38 MAP kinase pathway with 
subsequent cyclin D1 degradation (29); downregulation of 
Bcl-2 expression (30); activation of p53 and p21 dependent on 
the ATM checkpoint kinase (31); upregulation of 15-lipoxy-
genase-1 (32); the induction of expression of pro-apoptotic 
DNA repair proteins (33); inhibition of epidermal growth 
factor activation (34,35) and a prophylactic action wherein 
selection for microsatellite stability occurs (36). Studying 
variants of aspirin and related compounds may not only reveal 
more active/specific alternatives, but may also allow insight 
into the chemical components of the agents that are associated 
with these differing mechanistic activities.
We recently generated a panel of variants of salicylate 
in order to identify molecules that show the specific effects 
of aspirin against CRC, but with increased anti-prolifer-
ative activity. Of the compounds tested, ̔diaspirins’ [e.g. 
bis(2-carboxyphenyl) succinate] were noted to be significantly 
more toxic to CRC cells than aspirin yet appeared to retain 
some specificity to CRC cells (37).
Here, we extended this investigation. We generated novel 
compounds that are based on the ̔ diaspirins’ and demonstrated 
that these compounds had potent antitumour activity against 
CRC cells in vitro and in vivo, in a well characterised implant-
able mouse model of CRC. Investigation of the mechanism of 
action of these agents revealed that both agents stimulated the 
NF-κB pathway and repressed NF-κB-driven transcription. 
However, it also suggested that the mechanism underlying 
this repression differs between aspirin and the diaspirin 
compounds. These data identify novel anticancer compounds 
and shed light on the structure-activity relationships important 
for the pro-apoptotic response to aspirin.
Materials and methods
Materials. Dulbecco's modified Eagle's medium (DMEM) 
and fetal bovine serum (FBS) were obtained from PAA 
(Somerset, UK) or Sigma-Aldrich (Dorset, UK). Precision 
Plus Protein Colour standards and nitrocellulose were from 
Bio-Rad. RPMI-1640 medium, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide 
(DMSO) and propidium iodide were from Sigma-Aldrich. 
All other reagents were obtained from Sigma-Aldrich unless 
otherwise stated.
Compound synthesis. Diaspirin [bis(2-carboxyphenyl) succi-
nate; PN508] and fumaryl diaspirin [bis(2-carboxyphenyl) 
fumarate; PN517] were prepared as previously described (37). 
Aspirin is commercially available as acetylsalicylic acid, and 
the synthesis of the other compounds is as described in supple-
mentary information (provided upon request). The compounds 
tested are shown in Fig. 1.
Preparation of PN511 and PN512. These were prepared using 
the method described for PN508/PN517 (37) using sebacoyl 
chloride and terephthaloyl chloride, respectively. Both were 
recrystallised from 90/10 toluene ethanol mixture. PN511 is 
a white solid [mpt 135-136˚C; literature mpt 139-142˚C [see 
e.g. (45)]; IR (cm-1): 2917, 2854, 1754, 1683, 1604]. PN512 is a 
white solid [mpt 295-300˚C, IR (cm-1): 1736, 1698, 1605]. The 
molar masses of the products were confirmed as 442 and 406 
respectively by titration with standardised sodium hydroxide 
using the method described previously (37). Samples submitted 
for accurate mass spectrometry returned the following data: 
PN511 m/z (CI) 460.1964 (M + NH4
+, C24H26O8NH4 requires 
460.1966); PN512 m/z (CI) 424.1025 (M + NH4
+, C22H14O8NH4 
requires 424.1027).
Preparation of PN524 and PN525. PN524 was prepared by 
reaction of 3-bromobenzoyl chloride with salicylic acid in the 
presence of 1 mole-equivalent of pyridine. 3-Bromobenzoyl 
chloride is available commercially but can also be produced 
from 3-bromobenzoic acid by the action of excess thionyl chlo-
ride (SOCl2). Refluxing for 2-3 h (with trapping of the evolved 
gases) until all of the solid material had dissolved, followed by 
removal of any excess thionyl chloride by distillation, gave an 
almost quantitative yield that can be used immediately in the 
subsequent step. Salicylic acid (0.1 mol, 13.81 g) was dissolved 
in THF (50 ml) and stirred. Pyridine (0.1 mol, 8.2 ml) was 
then added and the mixture was stirred magnetically while 
3-bromobenzoyl chloride (~13.25 ml) was added slowly over 
2-3 min. The temperature rose to 35-40˚C during the addi-
tion. Pyridinium chloride was precipitated and stirring was 
continued for a further 12-24 h. Ice-cold water (200 ml) 
was then added and the mixture was stirred thoroughly. The 
mixture was extracted with diethyl ether (150 ml) by vigorous 
magnetic stirring. The ether layer was then separated and 
extracted with 10% Na2CO3 solution (150 ml) to remove the 
PN524 from unwanted by-products. The carbonate layer was 
then acidified with concentrated HCl until a precipitate was 
seen (pH 2.0-3.0). The precipitate was taken up in diethyl 
ether, separated and dried with anhydrous MgSO4 before 
rotary evaporation of the ether. A clean white solid (17.0 g, 
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53%) was obtained. Recrystallisation was achieved from 
boiling hexane with some acetone added, by cooling to -15˚C 
for 24-36 h. White crystals were obtained [mpt 140-142˚C; IR 
(cm-1): 3068, 1738, 1682, 1605]. The molar mass of the product 
was confirmed as 321 by titration with standardised sodium 
hydroxide using the method described previously (37).
PN525 was prepared in an analogous way using 4-methyl-
benzoyl chloride in place of 3-bromobenzoyl chloride. The 
product is a white solid and was recrystallized from toluene 
[mpt 148-150˚C, IR (cm-1): 1734, 1674, 1605]. The molar 
mass of the product was confirmed as 256 by titration with 
standardised sodium hydroxide using the method described 
previously (37).
Preparation of PN528. Methyl salicylate (13.0 ml) was placed 
in a 100-ml conical flask. Pyridine (8.1 ml) was then added and 
the mixture was stirred magnetically while benzoyl chloride 
(11.6 ml) was added slowly over 2-3 min. The temperature rose 
to 48-50˚C during the addition. Crystals of pyridinium chlo-
ride precipitated and stirring was continued for a further 2 h. 
Hexane (50 ml) was then added and the mixture was stirred 
thoroughly. The resulting heavy white precipitate (~35 g) was 
filtered and allowed to air dry before being shaken vigor-
ously with water (100 ml) to dissolve the pyridinium chloride 
by-product. The remaining solid was filtered under vacuum 
and dried at 60˚C. The yield was 15-16 g (~65%). This crude 
product had a mpt of 82-85˚C. The product was recrystallised 
by dissolving in the minimum volume of hot acetone and then 
adding hot hexane until the solution just remained clear. The 
solution was then cooled to -15˚C for a minimum of 24 h. A 
white solid [12.0 g, mpt 84-86˚C; IR (cm-1): 1737, 1715, 1605] 
was obtained. The literature mpt is 83.8-84˚C (51).
Preparation of PN529. Isopropyl salicylate was reacted with 
a slight excess of 3-bromobenzoyl chloride in the presence 
of pyridine with no additional solvent. Isopropyl salicylate is 
available commercially but we also prepared small quantities 
from 2-propanol and salicylic acid by refluxing them with 
a catalytic quantity of concentrated H2SO4. A ratio of 25 g 
salicylic acid to 100 ml 2-propanol was used with 1-2 ml of 
concentrated H2SO4. After a minimum of 12 h refluxing, the 
excess 2-propanol was removed by rotary evaporation. The 
residue of oily solid was shaken with 10% NaHCO3, with 
more solid bicarbonate added until all the unreacted salicylic 
acid had dissolved. This mixture was then extracted well with 
diethyl ether before separating the ether layer, drying over 
anhydrous MgSO4 and removing the ether by rotary evapo-
ration. A low yield (3-5 g; 9-15%) of almost pure isopropyl 
salicylate (tlc) was obtained and used without further purifica-
tion. 3-Bromobenzoyl chloride was obtained as described for 
the preparation of PN524 above. Isopropyl salicylate (1.90 g) 
was mixed with pyridine (1.6 ml) and was then added carefully 
to 3-bromobenzoyl chloride (2.38 g). An immediate reac-
tion produced a near-solid product. The reaction vessel was 
protected with a silica gel guard tube and left at room tempera-
ture for 2-3 days to complete the reaction. Water (20 ml) was 
added to the tube which was stoppered and shaken vigorously. 
A sticky oil was released which was taken up in diethyl ether, 
washed with 10% NaHCO3 (20 ml) and then water (20 ml). 
The ether layer was dried over anhydrous MgSO4 and rotary 
evaporated to give a clear, pale yellow oil (3.4 g; 87%). A solid 
product was obtained by dissolving the oil in a little warm 
diethyl ether and then diluting with boiling hexane or light 
petroleum ether until a cloudy solution was observed. Storing 
this mixture at -15˚C for 2-3 days gave white crystals [mpt 
49-51˚C, IR (cm-1): 2979, 1735, 1703, 1606].
Cell culture. The human colorectal adenocarcinoma cell line 
SW480 (supplied by ECACC) was cultured in Leibovitz's 
L-15 medium containing 10% (v/v) FBS supplemented with 
1% L-glutamine-penicillin-streptomycin (Sigma-Aldrich). 
The human colorectal adenocarcinoma cell lines Lovo and 
HCT-116, the human breast carcinoma cell line MCF-7 and the 
human endothelial cell line EA.hy926 were all kindly provided 
by Dr Wang (University of Wolverhampton) and maintained 
in DMEM containing 10% (v/v) FBS supplemented with 1% 
L-glutamine-penicillin-streptomycin (Sigma-Aldrich). The 
A549 human lung adenocarcinoma cell line was provided 
by Dr Safrany (University of Wolverhampton) and main-
tained in RPMI-1640 medium supplemented with 10% 
FBS with 1% L-glutamine-penicillin-streptomycin. In cyto-
toxicity experiments for IC50 determinations, to minimize 
medium-specific variation, cells were cultured and tested in 
DMEM containing 10% (v/v) FBS supplemented with 1% 
L-glutamine-penicillin-streptomycin. The murine adeno-
carcinoma cell line MAC13 [supplied by Professor Double, 
University of Bradford (38)] was maintained in RPMI-1640 
medium supplemented with 10% FBS/1% pen/strep solu-
tion/1% glutamine. The SW480 cell line was maintained in 
L-15 medium, was cultured at 37˚C and regularly passaged at 
~80% confluency. All other cells were cultured at 37˚C in a 
humidified incubator with 5% CO2 and regularly passaged at 
~80% confluency.
Evaluation of the anti-proliferative effect. Compounds were 
prepared as a stock (0.5 M) in DMSO, prior to addition to 
cells. The cytotoxic effect of aspirin and the other novel 
compounds was evaluated using the MTT assay (39) with 
modification (40). Briefly, 104 cells/well were cultured over-
night in 96-well microtitre plates. Twenty-four hours after the 
initial seeding, the culture medium was discarded, and the 
cells were incubated with medium containing drugs at the 
requisite concentration and incubated for the tested time at 
37˚C, then replaced with medium containing 300 µl of 0.5 mg/
ml MTT per well and incubated for 3 h at 37˚C, then replaced 
with 200 µl of DMSO and incubated for 10 min at 37˚C to 
develop a coloured formazan complex. Absorbance was 
recorded at 540 nm using a visible plate reader (Labsystems 
Multiskan MS). viability is reported as the percentage of 
treated cells relative to the cells in control wells. Compound 
anti-proliferative activity, stated as IC50 values, was deter-
mined by interpolation or using non-linear regression analysis 
using graphPad Prism Statistics Software package (ver. 6.0; 
San Diego, CA, USA).
For the evaluation of toxicity (in vitro) to the MAC13 cell 
line, when plated cells reached 90% confluency they were 
treated with either PBS, aspirin, DiA or F-DiA dissolved in 
PBS. After 48 h at 37˚C the cells were washed in PBS twice 
before 0.5 ml trypsin-EDTA (10%) was added, and the cell 
numbers were determined using a Coulter Counter.
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Preparation of drugs. For evaluation of the activity described 
in Figs. 3-5, the compounds were prepared as a 1 M stock 
solution in DMSO and sonicated to achieve solubility. DMSO 
concentrations never exceeded 0.5% of the medium volume. 
The medium containing drugs was sonicated until all visible 
particles were dissolved. The pH was subsequently adjusted 
to 7.6 with NaOH. Aspirin (Sigma, USA) was solubilized in 
water using 10 M NaOH and the pH was adjusted to 7.0.
Apoptosis assays. Staining for cell surface phosphatidylserine 
residues was carried out using an Annexin v-FITC apoptosis 
detection kit (Oncogene Research Products) according to 
the manufacturer's instructions. The percentage of apoptotic 
cells was measured using BD FACS Aria II (BD Biosciences, 
Franklin Lakes, Nj, USA). A negative control without the 
Annexin v-FITC antibody and DAPI were used to assess the 
background signal.
Cell cycle analysis. After drug treatment, SW480 cells were 
trypsinized and pelleted for 5 min at 1,600 rpm. The superna-
tant was removed. The cells were suspended in 100 µl citrate 
buffer and 450 µl of solution A [10 mg trypsin type IX-S in 
500 ml stock solution (2 g trisodium citrate, 121 mg Tris-base, 
1044 mg spermine tetrahydrochloride, 2 ml Nonidet NP-40 
in 2 l dH2O, pH 7.6)] was added to the samples and vortexed 
for 2 min. Subsequently, 375 µl solution B (250 mg trypsin 
inhibitor, 50 mg RNAse A in 500 ml stock solution, pH 7.6) 
was added to the samples, vortexed briefly and incubated for 
10 min at room temperature. Next, 250 µl solution C (208 mg 
propidium iodide, 500 mg spermine tetrahydrochloride in 
500 ml stock solution, pH 7.6) was added to the samples and 
vortexed briefly and incubated on ice in the dark for 10 min. 
Distribution of cells in the different phases of the cell cycle 
was analysed using BD FACS Aria II.
Transfections and reporter assays. For the analysis of 
NF-κB-driven transcription, cells were transfected with the 
3' enhancer CONA (3x κB ConA-Luc) (supplied by Professor 
R.T. Hay, University of Dundee) and pCMv-β-galactosidase 
(Promega) plasmids as described previously (41). The relative 
luciferase activity was calculated as units of luciferase activity 
per unit of β-galactosidase activity.
Western blot analysis. Following treatment, cytoplasmic and 
nuclear extracts were prepared as previously described (42). 
The protein concentration was determined using a Bradford 
assay (Bio-Rad). Protein extracts (20-50 µg) were resolved 
using discontinuous SDS-PAgE with a 10% gel, and 
immunoblotting was conducted using standard procedures. 
Primary antibodies used were: rabbit anti-cyclin D1 (Thermo 
Scientific, USA; 1:1000), sheep anti-IκB (a kind gift from R.T. 
Hay) and mouse anti-actin as a loading control. Proteins were 
detected using western blotting luminol reagent (Santa Cruz, 
USA). Imagej software (NIH) was employed for densitometric 
analysis of the western blots.
Implantable mouse CRC model. NMRI nude mice from the 
Aston colony were treated with MAC13 cells (5x106) sub-cut 
into their flanks. Once the tumour was established, it was 
dissected and small fragments were re-transplanted (subcuta-
neously) into more mice. Mice (~20 g in weight) were selected 
at random and administered PBS or DiA or F-DiA, dissolved 
in PBS (1 mg/kg) intravenously. Animals were randomly 
divided (6 animals/group). Medication was administered 
intravenously daily. The mice were monitored daily for weight, 
food and water consumption. Tumour size was recorded using 
callipers. Prior to the animal model experiment, as much as 
5 mg/kg compound was given to several control mice and 
no toxicity was observed (data available upon request). The 
experiment ended when the control mouse tumours started to 
ulcerate. All animal experiments were conducted under Home 
Office Licence in accordance with the UK Animals (Scientific 
Procedures) Act 1986.
Statistical analysis. values are expressed as means ± SD or 
SEM. To evaluate the difference in means between groups 
in the animal study, one-way ANOvA followed by Tukey's 
post-hoc test was undertaken.
Results
Aspirin analogues demonstrate potent activity against CRC 
cells. To understand the molecular basis for the antitumour 
effects of aspirin and identify more effective alternatives, we 
previously synthesised a series of derivatives of the aspirin 
molecule. These studies revealed that diaspirin (DiA) and 
fumaryl diaspirin (F-DiA) inhibit proliferation of CRC cell 
lines at significantly lower concentrations than aspirin (37). To 
extend these studies and identify further lead molecules, we 
synthesised an additional series of aspirin derivatives (Fig. 1). 
Cytotoxicity (MTT) assays demonstrated that at 0.5 mM 
(pharmacologically relevant dose for aspirin), DiA (PN508) 
and F-DiA (PN517) and to an even greater extent, isopropyl 
m-bromobenzoylsalicylate (PN529) reduced the viability of 
SW480 CRC cells (Fig. 2A). To investigate the specificity of 
compound toxicity in more detail, we tested the capacity of 
DiA, F-DiA and PN529 to affect proliferation of a number of 
established cell lines in vitro (Fig. 2B and Table Ι), controlling 
for any variability that could arise from cell culture conditions 
through culturing all cells with DMEM as the basal medium. 
While we noted that culturing SW480 cells in their non-native 
medium (DMEM rather than L-15 medium) reduced the sensi-
tivity of the cells to the compounds tested, DiA and F-DiA in 
this assay system arguably showed a modicum of specificity 
towards the other CRC cell lines tested (HCT116 and Lovo), 
and given our finding that PN529 can induce necrosis (37), we 
focused our attention on the anti-proliferative activity of DiA 
and F-DiA in more detail in vitro and in vivo.
The major anti-proliferative effect of aspirin is recognised 
to be the induction of apoptosis. However, the mechanism by 
which DiA and F-DiA act against CRC cells is as yet unknown. 
To further understand this mechanism, we used Αnnexin v 
assays to investigate the effects of aspirin derivatives on 
apoptotic cell death. We found that both compounds (3 mM) 
induced a significant increase in the percentage of SW480 
CRC cells undergoing apoptosis, compared to the carrier 
(DMSO)-treated controls (Fig. 3). This increase in apoptosis 
was paralleled by a decrease in the percentage of viable cells, 
confirming the death-inducing capacities of the agents (data 
not shown). Time course studies revealed that 3 mM F-DiA 
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mediated a significant increase in apoptosis within 3 h of treat-
ment (Fig. 3), while a more prolonged (>5 h) exposure was 
required before DiA-mediated apoptosis was evident (data 
not shown). In contrast to the diaspirin compounds, aspirin at 
3 mM had minimal effect on cell growth/death after an 18-h 
exposure (data not shown), which is in keeping with previous 
studies showing that 5 mM aspirin is required to induce detect-
able apoptosis of these cells within this time frame (41). Taken 
together, these data indicate that the diaspirin compounds 
induce apoptosis of CRC cells and that this occurs at a lower 
concentration than for aspirin and that F-DiA is the more 
active of the compounds.
Aspirin analogues induce the degradation of cyclin D1, but 
do not affect cell cycle distribution. Having established that 
the aspirin analogues induce apoptosis, we next aimed to 
determine whether the underlying mechanism is similar to 
that of aspirin. Understanding the mechanism of action of 
these agents may not only identify novel apoptotic pathways, 
but may also reveal structural aspects of aspirin that are 
important for its antitumour activity. Degradation of cyclin 
D1 is an early response to aspirin and is critical for its apop-
totic activity (29). Therefore, we firstly examined the effects 
of the agents on cellular levels of this protein. We found that 
both DiA (3 mM, 18 h) and F-DiA (3 mM, 18 h) induced a 
marked decrease in cyclin D1 levels (Fig. 4A). Furthermore, 
this decrease was time-dependent and for both agents, 
preceded the induction of apoptosis (Fig. 4B). However, 
unlike the g2/M cell cycle arrest observed in response to 
aspirin, DiA- and F-DiA-mediated depletion of cyclin D1 
was not associated with significant changes in the cell cycle 
profile (Fig. 4C).
Aspirin analogues stimulate the NF-κB pathway. NF-κB is a 
ubiquitously expressed transcription factor that plays a critical 
role in cell growth and death. It generally resides in the cyto-
plasm as a heterodimer of the RelA/P50 subunits, bound to 
the inhibitor protein, IκB. In response to a variety of agents, 
IκB is degraded allowing NF-κB to translocate to the nucleus 
and regulate expression of target genes. Thoms et al previously 
demonstrated that aspirin-induced degradation of cyclin D1 is 
linked to the induction of apoptosis through stimulation of this 
pathway (29). Moreover, cyclin D1 is transcriptionally activated 
by NF-κB. To determine whether DiA- and F-DiA-mediated 
depletion of cyclin D1 and induction of apoptosis are also 
Figure 1. Structure of the compounds examined in the present study. 
Table I. IC50 values (mM) for compounds using the MTT assay 
to selected colorectal and non-colorectal cancer cell lines.
 Compound (mM)
 --------------------------------------------------------------------------------------
 PN508 PN517 PN529
Cell lines
  SW480 2.43±0.1 0.87±0.05 0.24±0.06
  HCT116 1.08±0.2 1.47±0.1 0.15±0.01
  Lovo 1.59±0.2 1.17±0.08 0.14±0.01
  A549 2.3±0.1 1.47±0.08 0.13±0.001
  MCF-7 2.4±0.2 1.62±0.2 0.15±0.04
  EA.hy926 6.2a 1.68±0.09 0.24±0.2
IC50 values were obtained by interpolation and are expressed as 
the mean ± SEM of the data from three independent experiments. 
aObtained by extrapolation using non-linear regression.
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Figure 2. Cytotoxicity of aspirin analogues to selected cancer cell lines in vitro. (A) SW480 cells were plated at a density of 104 cells/ml in 96-well microtitre 
plates (200 µl/well) in a L-15-based medium. Twenty-four hours after seeding, the cells were treated with compound-containing culture medium for a further 
72 h. The anti-proliferative effects were measured in an MTT assay. All compounds were dissolved in DMSO. Mean ± SEM is shown (N=3). The effect of sali-
cylic acid (SA) and aspirin (ASP) is included for comparison. (B) Sensitivity of selected colorectal (SW480, HCT116, Lovo) and non-colorectal (A549, MCF7, 
EA.hy926) cancer cell lines cultured in DMEM-based culture medium, to diaspirin (PN508), fumaryl diaspirin (PN517) and isopropyl m-bromobenzoyl 
salicylate (PN529). Twenty-four hours after seeding, the cells were treated with compound-containing culture medium for a further 72 h. The anti-proliferative 
effects were measured in an MTT assay. All compounds were dissolved in DMSO. Each point represents the mean ± SD (N=3). Circle, carrier molecule 
(DMSO); square, PN508 (DiA); triangle, PN517 (F-DiA); diamond, PN529. 
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associated with modulation of NF-κB signalling, we firstly 
examined the effects of these agents on IκBα. Fig. 5A demon-
strates that both DiA and F-DiA induced a marked decrease in 
cytoplasmic levels of this protein, suggestive of proteasome-
mediated degradation.
Following aspirin-mediated degradation of IκB, RelA 
translocates from the cytoplasm to the nucleoplasm and then 
to a nuclear compartment, the nucleolus (41,43). This nucleolar 
compartmentalisation of RelA causes a reduction in basal 
levels of NF-κB transcriptional activity, which is critical 
for the apoptotic effects of the agent. Immunocytochemical 
analysis demonstrated that DiA and F-DiA induced a substan-
tial increase in nucleoplasmic RelA, confirming that these 
agents stimulated the NF-κB pathway. However, in contrast 
to aspirin, the protein did not accumulate specifically in 
nucleoli (Fig. 5B and C). Time-course studies demonstrated 
that for both compounds, translocation of RelA to the 
nucleoplasm was subsequent to degradation of cyclin D1, 
but preceded the induction of apoptosis (Fig. 5C). They also 
demonstrated that F-DiA-mediated nucleoplasmic accumula-
tion of RelA was more rapid and significant than that induced 
by DiA, in keeping with the apoptotic effects of the agents. 
Indeed, nucleoplasmic RelA was evident within 1 h of F-DiA 
treatment and cells appeared dead within 3 h.
In response to specific stresses, nucleoplasmic NF-κB/RelA 
complexes have been shown to mediate apoptosis by repressing 
basal NF-κB-driven transcription (44). To examine this as a 
possible mechanism for the apoptotic effects of the diaspirin 
compounds, we next performed NF-κB reporter assays. 
We found that both DiA and F-DiA induced a significant 
decrease in basal levels of NF-κB transcriptional activity. This 
decrease was more pronounced than for aspirin, occurred in a 
time-dependent manner and was subsequent to nucleoplasmic 
accumulation of RelA (Fig. 5C and D). Furthermore, similar 
to depletion of cyclin D1, nucleoplasmic accumulation of RelA 
and the induction of apoptosis, we found that F-DiA had a 
more rapid and profound effect on NF-κB-driven transcription 
than DiA (Fig. 5E). These data suggest that, similar to aspirin, 
the diaspirin compounds stimulate the NF-κB pathway and 
mediate apoptosis through repression of NF-κB-driven tran-
scription. However, they also suggest that the mechanism 
underlying this repression differs between aspirin and the 
related agents.
Figure 3. Aspirin analogues mediate apoptosis. SW480 cells were either 
(A) left untreated (NT) or treated with DMSO (final concentration as for DiA 
and F-DiA), 3 mM aspirin, 3 mM DiA or 3 mM F-DiA for 16 h or, (B) treated 
with 3 mM F-DiA for the times specified. (A and B) The percentage of cells in 
the population undergoing apoptosis was determined using Annexin v-FITC 
apoptosis assays. Data presented are the minimum of three independent 
experiments (± SEM). (A) The percentage of cells undergoing apoptosis 
was compared for aspirin vs. NT and DiA and F-DiA vs. DMSO. (B) The 
percentage of cell undergoing apoptosis at each time point was compared to 
time 0. *P<0.05 using a Student's t-test.
  A
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Figure 4. Aspirin analogues induce degradation of cyclin D1. SW480 cells 
were either (A) left untreated (NT) or treated with DMSO (final concentra-
tion as for DiA and F-DiA), 3 mM aspirin, 3 mM DiA or 3 mM F-DiA for 
16 h, or (B) treated with 3 mM DiA or 3 mM F-DiA for the times specified. 
(A and B) Western blot analysis was performed on cytoplasmic extracts with 
antibodies to cyclin D1. Actin was used as a loading control. (B) Band inten-
sities were quantified and cyclin D1 levels calculated relative to actin. Data 
presented are the mean of three individual experiments ± SEM. (C) SW480 
cells were treated as for A, and then the proportion of cells in each phase of 
the cell cycle was analysed. The graph shows the mean of 3 experiments ± the 
SEM. Aspirin (Asp) influenced the proportion of cells in each phase of the 
cell cycle after treatment. However, this was not observed for DiA or F-DiA. 
  A
  B
  C
CLAUDIUS et al:  DIASPIRINS AND ACTIvITy TOWARDS COLORECTAL CANCER in vitro AND in vivo 1677
Inhibition of tumour growth by diaspirins in an implantable 
CRC mouse model. Taken together, the above data suggest that 
the diaspirin compounds, particularly F-Dia, have potent activity 
against CRC cells. To determine whether these effects translate 
into in vivo potency, we utilised the well characterised MAC13 
syngeneic mouse model of CRC (38). In the cytotoxicity assays 
Figure 5. Aspirin analogues stimulate the NF-κB pathway and cause repression of NF-κB-driven transcription. (A) SW480 cells were either left untreated 
(NT) or treated with 3 mM aspirin, DiA or F-DiA for 16 h. TNF-α (30 min) was used as a positive control for IκB degradation. Western blot analysis was 
performed on cytoplasmic extracts with antibodies to IκBα. Actin was used as a control for protein loading. DiA and F-DiA induced degradation of IκB. (B 
and C) Anti-RelA immunocytochemistry was performed on cells treated with (B) DMSO, aspirin (5 mM) or the specified concentration of DiA or F-DiA for 
16 h, or (C) 3 mM DiA or F-DiA for the times specified. DiA and F-DiA induced nuclear translocation of RelA. (D and E) SW480 cells were transfected with 
6 µg of NF-κB-dependent luciferase reporter construct (3 x κB ConA) along with 3 µg of pCMvβ control plasmid. Twenty-four hours after transfection, cells 
were treated with (D) DMSO, aspirin (3 mM), DiA or F-DiA for a further 16 h, or (E) 3 mM DiA or F-DiA for the times specified. Results were normalised 
using β-galactosidase activity and are presented as the percentage of relative luciferase activity compared to basal levels (DMSO controls). The average of at 
least three independent experiments is shown ± SEM. 
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MAC13 cells cultured in vitro were more sensitive to DiA and 
F-DiA than aspirin (data not shown); in vivo, the mouse colon 
carcinoma cells were implanted subcutaneously into NMRI 
mice and treatment commenced 12 days after implantation. 
Low dose (1 mg/kg) DiA or F-DiA was administered every 
day for 10 days by intravenous injection. No overt side-effect 
was observed between the treatment and vehicle-treated control 
group, and food and water intake was unaffected. As shown in 
Fig. 6, treatment with DiA and F-DiA significantly inhibited 
the growth of the tumours, and almost complete suppression of 
growth was apparent in the mice treated with F-DiA.
Discussion
Colon cancer is a major cause of cancer-related mortality 
worldwide, particularly in Western societies. Present thera-
pies are associated with significant morbidity and generally 
provide marginal benefit. Hence, there is an overwhelming 
rationale for novel developments that would lead to a reduction 
in incidence and/or in cancer-related morbidity and mortality. 
Herein, we demonstrated that two analogues of aspirin had 
greater anti-proliferative activity against CRC cells in vitro 
than aspirin and salicylate and that these compounds exhibited 
a modicum of specificity for CRC cell lines in vitro [Fig. 2, 
Table I and ref. (37)]. Furthermore, we also demonstrated that 
DiA and F-DiA had potent antitumour activity in vivo, in an 
implantable mouse model of CRC (Fig. 6) and showed no 
obvious side-effects when introduced to mice intravenously 
over a 10-day period. Taken together, these data identify DiA 
and F-DiA as potential novel therapeutic agents for CRC. 
Although a collection of related structures termed ̔diaspirins’ 
[in particular bis(3,5-dibromosalicyl) fumarate] have long 
been known to cross link haemoglobin (45), as far as we are 
aware, this is the first report of the antitumour properties of 
these agents.
The phenotypic studies indicated that the diaspirin 
compounds were capable of inducing apoptosis (Fig. 3). 
On analysis of the mechanisms underlying this apoptosis, 
we found that similar to aspirin, the diaspirin compounds 
sequentially induced depletion of cyclin D1, degradation of 
IκB, nuclear translocation of NF-κB/RelA complexes and 
repression of NF-κB activity. However, in contrast to aspirin, 
the aspirin analogues did not induce nucleolar translocation 
of RelA or cell cycle arrest. Aspirin consists of acetyl and 
salicylate moieties, both of which have their own individual 
targets (46). The aspirin analogues we generated retained the 
salicylate part of the molecule but lost the acetyl component. 
Indeed, western blot analysis with antibodies against acety-
lated lysine indicated that aspirin induced a dose-dependent 
increase in protein acetylation, but this was not observed in 
response to DiA and F-DiA (data not shown). Therefore, one 
possibility is that the ability of aspirin to stimulate NF-κB 
signalling is associated with the salicylate component of the 
compound while nucleolar translocation of RelA and cell cycle 
arrest are associated with its acetylating potential. In keeping 
with this suggestion, salicylate has previously been shown to 
activate p38 kinase activity (47), which we have previously 
shown lies upstream of aspirin effects on cyclin D1 and the 
NF-κB pathway (29).
Constitutive activity of NF-κB has been shown to contribute 
to carcinogenesis in a number of cancer types, including 
CRC (48). We previously demonstrated that aspirin-mediated 
nucleolar sequestration of RelA induces apoptosis, at least in 
part, by causing repression of this basal NF-κB transcriptional 
activity (41). Here, we found that the aspirin analogues also 
mediated a reduction in basal levels of NF-κB-driven transcrip-
tion. Furthermore, we found that this reduction preceded the 
induction of apoptosis. The effects of the diaspirin compounds 
on NF-κB transcriptional activity were more pronounced than 
for aspirin, in keeping with the enhanced apoptotic activity of 
these agents. Taken together, these data suggest that similar to 
aspirin, the analogues mediate apoptosis by repressing NF-κB-
driven transcription. We note that the NSAID ibuprofen can 
induce IκBα degradation, NF-κB nuclear localization and 
suppression of cyclin D1 expression (49).
As outlined above, we did not observe nucleolar seques-
tration of RelA in response to the diaspirin compounds, 
suggesting that an alternative mechanism is responsible for 
the effects of these agents on NF-κB transcriptional activity. 
Campbell et al (44) previously demonstrated that stimula-
tion of the NF-κB pathway by specific pro-apoptotic stimuli 
causes nucleoplasmic accumulation of repressive RelA/NF-κB 
complexes that mediate apoptosis by recruiting histone 
deacetylases (HDACs) to the chromatin of NF-κB-regulated 
anti-apoptotic genes. We previously demonstrated that aspirin 
induces the ubiquitination of RelA, which targets the protein 
to the nucleolus (50). Therefore, it may be that in the absence 
of the acetylating component of aspirin, nucleoplasmic RelA 
cannot be ubiquitinated, allowing the recruitment of alterna-
tive repressive factors such as HDACs. Our finding that, of the 
two compounds, F-DiA had the most rapid effect in all of the 
mechanistic assays and the most significant activity against the 
growth of implanted tumour adds weight to our suggestion that 
the antitumour activity of this agent is caused by modulation 
of NF-κB signalling. It also identified F-DiA as particularly 
significant for therapy development. From the range of 
analogues studied to date it would seem that increased activity 
is at least, in part, associated with the presence of two (or 
Figure 6. Effect of diaspirin and fumaryl diaspirin on an implantable 
colorectal mouse tumour model. MAC13 cells were implanted subcutane-
ously into the flank of three groups (N=6) of NMRI mice. Twelve days after 
implantation, mice were intravenously administered 1 mg/kg DiA or F-DiA 
daily, while the control group received PBS. The results demonstrate a robust 
inhibition of growth in the drug-treated groups, which were significantly 
different from the control group (*P<0.001 from PBS control by one-way 
ANOvA followed by Tukey's post-hoc test). 
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perhaps more) suitably spaced aromatic rings and indicates the 
significance of two salicylate moieties in the molecule sepa-
rated by ~8-10Å. We speculate that F-DiA may demonstrate 
greater toxicity as a consequence of its greater symmetry and 
reduced number of conformers.
To conclude, we identified diaspirins that have potent 
anti-proliferative activity against CRC cells in vitro and 
in vivo. The in vitro mechanistic studies provide compelling 
evidence that these agents exert their anti-proliferative effects 
against SW480 cells by causing repression of NF-κB-driven 
transcription. The mechanistic studies also helped to elucidate 
structure-function relationships for the aspirin molecule. In 
particular, these findings provide insight into the mechanisms 
of action of F-DiA and support further studies into the poten-
tial of F-DiA as a chemotherapeutic agent. We wish to test 
these agents in models of cachexia and in genetically defined 
mouse models [e.g. Apc(Min/+) and Apc(Min/+), Msh2(-/-)] of 
CRC. We acknowledge, however, that formal dose ranging and 
toxicity studies with, for example, clinical scoring of gastroin-
testinal toxicity does need to be undertaken.
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